A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants
PHASE1CompletedINTERVENTIONAL
Enrollment
88
Participants
Timeline
Start Date
February 13, 2023
Primary Completion Date
October 30, 2023
Study Completion Date
October 30, 2023
Conditions
Healthy
Interventions
DRUG
LY4100511
Administered orally
Trial Locations (1)
M23 (QZ
The Medicines Evaluation Unit Ltd., Manchester
All Listed Sponsors
lead
Eli Lilly and Company
INDUSTRY
NCT06937411 - A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants | Biotech Hunter | Biotech Hunter